Denovo Biopharma is a clinical-stage biopharmaceutical company focused on the development of biomarker-driven precision medicines. Our technology platform can be broadly applied to biomarker discovery and biomarker-guided drug development in many therapeutic areas such as oncology, neurology, metabolic, cardiology, and immunology.
A Novel Strategy to Discover Clinical Biomarkers Retrospectively with Archived Samples
Many drugs unfortunately fail after large and expensive Phase 3 studies have been completed,
largely due to lack of efficacy or undesirable adverse effects. Our technology can enable drug developers to
design new clinical trials in smaller and targeted patient populations at lower cost than the previous
studies, providing a personalized medicine approach.
A highly novel aspect of this technology is that plasma samples can be
used to identify novel genetic biomarkers by scanning the entire human genome and conducting a proprietary
data analysis developed internally by Denovo. This type of testing has not been possible in the past using
other technologies.
